GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (XTER:ZEG) » Definitions » Cyclically Adjusted PS Ratio

AstraZeneca (XTER:ZEG) Cyclically Adjusted PS Ratio : 4.72 (As of Jun. 29, 2025)


View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PS Ratio?

As of today (2025-06-29), AstraZeneca's current share price is €120.05. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €25.44. AstraZeneca's Cyclically Adjusted PS Ratio for today is 4.72.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PS Ratio or its related term are showing as below:

XTER:ZEG' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.69   Med: 4.92   Max: 6.78
Current: 4.81

During the past years, AstraZeneca's highest Cyclically Adjusted PS Ratio was 6.78. The lowest was 2.69. And the median was 4.92.

XTER:ZEG's Cyclically Adjusted PS Ratio is ranked worse than
77.4% of 739 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs XTER:ZEG: 4.81

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share data for the three months ended in Mar. 2025 was €8.052. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €25.44 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PS Ratio Chart

AstraZeneca Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.89 5.51 6.30 5.52 5.02

AstraZeneca Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.45 6.17 5.70 5.02 5.30

Competitive Comparison of AstraZeneca's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


;
;

AstraZeneca Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AstraZeneca's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=120.05/25.44
=4.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=8.052/136.1000*136.1000
=8.052

Current CPI (Mar. 2025) = 136.1000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 4.442 100.100 6.040
201509 4.187 100.200 5.687
201512 4.644 100.400 6.295
201603 4.341 100.400 5.885
201606 3.942 101.000 5.312
201609 4.011 101.500 5.378
201612 4.182 102.200 5.569
201703 3.992 102.700 5.290
201706 3.551 103.500 4.669
201709 4.127 104.300 5.385
201712 3.844 105.000 4.983
201803 3.314 105.100 4.291
201806 3.483 105.900 4.476
201809 3.612 106.600 4.612
201812 4.452 107.100 5.657
201903 3.832 107.000 4.874
201906 3.928 107.900 4.955
201909 4.433 108.400 5.566
201912 4.568 108.500 5.730
202003 4.380 108.600 5.489
202006 4.244 108.800 5.309
202009 4.257 109.200 5.306
202012 4.639 109.400 5.771
202103 4.662 109.700 5.784
202106 5.176 111.400 6.324
202109 5.606 112.400 6.788
202112 6.805 114.700 8.075
202203 6.625 116.500 7.740
202206 6.532 120.500 7.378
202209 7.115 122.300 7.918
202212 6.782 125.300 7.367
202303 6.513 126.800 6.991
202306 6.754 129.400 7.104
202309 6.903 130.100 7.221
202312 7.063 130.500 7.366
202403 7.477 131.600 7.733
202406 7.705 133.000 7.885
202409 7.825 133.500 7.977
202412 9.104 135.100 9.171
202503 8.052 136.100 8.052

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (XTER:ZEG) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AstraZeneca Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines